Tribute Pharmaceuticals Canada Inc.

March 21, 2013 07:30 ET

Tribute Pharmaceuticals Reports 2012 Year-End Results with Strong Revenue Growth

MILTON, ONTARIO--(Marketwire - March 21, 2013) - Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF)(OTCBB:TBUFF) ("Tribute" or "the Company"), a Canadian specialty pharmaceutical company, today announced financial results for the year ended December 31, 2012. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).

2012 Year-End Highlights:

  • Revenues increased 219% to $12,342,800 from $3,869,900 for the year ended December 31, 2011
  • Gross profit was up 113% to $5,168,900 from $2,426,500 for the year ended December 31, 2011
  • Expanded Canadian national sales force to support growing product portfolio and revenues
  • In October, 2012 launched novel migraine headache treatment CAMBIA® into the Canadian migraine market
  • Acquired exclusive Canadian rights to Collatamp G® to compete in the post-operative infection prevention market
  • Signed agreement with Pfizer Canada for exclusive promotional rights in Canada for Gelfoam® addressing the hemostatic device market
  • Subsequent to the 2012 year-end, in March 2013 Tribute raised US$4,545,000 from the sale of its equity securities with over 50% participation from insiders

Total revenue for the year ended December 31, 2012 increased by 219% to $12,342,800 compared to $3,869,900 in 2011, driven by an increase in licensed domestic product sales. The Company was also able to add two new products to our Specialty Care group in 2012 with Collatamp G and Gelfoam and the launch of Cambia significantly bolstered the product portfolio for our Primary Care sales force. The Company now has nine product lines as of December 31, 2012. MycoVa™ is currently the only product not approved in Canada.

Gross profit in 2012 increased by 113% to $5,168,900 over 2011 gross profit of $2,426,500. The increase was due to sales and corresponding gross profits from the larger number of approved and marketed products in the Company's portfolio.

Selling, general and administrative expenses for the year ended December 31, 2012 were $8,870,600 compared to $3,034,700 in 2011. The increase of $5,835,900 or 192% is primarily due to a significant investment in the expansion of the Company's sales force and marketing expenses to grow its existing products, marketing and sales expenses related to the launch of Cambia®, as well as an increase in business development.

Net loss for the year ended December 31, 2012 was $3,349,000, compared to a net loss in the prior year of $521,800. This equates to a loss of $0.09 per basic and diluted share in 2012 compared to a loss of $0.02 per basic and diluted share in 2011.

As of December 31 2012, the Company had cash and cash equivalents of $2,283,900.

"In 2012 we successfully executed on our growth strategy and built the foundation for further growth in 2013 and beyond. Our confidence and belief in Tribute's value as a company is evidenced by the fact that key members of our management team including our CFO and CSO, and board of directors, including myself, have personally increased our investment through an equity funding in the Company this month," stated Tribute's President and CEO Rob Harris.

"Expanding our product portfolio as well as our Canadian sales force in 2012 enabled us to increase our revenues over 2011 levels. We also added key management including a Vice President of Sales and a Chief Scientific Officer. These are the building blocks that provide infrastructure for our continued growth in 2013. We are actively looking to add more products to our domestic sales portfolio in Canada, which will be supported by our expanded sales force. We are also looking for further growth through distribution agreements for our internally developed products and products for which we have marketing rights in countries where we do not yet have distribution agreements."

About Tribute Pharmaceuticals Canada Inc.

Tribute is an emerging Canadian specialty pharmaceutical company focused on the acquisition, licensing, development and management of pharmaceutical and healthcare products with its primary focus on the Canadian market.

Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution), Uracyst® (sodium chondroitin sulfate solution 2%), Collatamp G® and Gelfoam® in the Canadian market. Additionally, NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships.

Tribute's Forward-Looking Statement

This press release contains certain forward-looking statements about Tribute as defined in the Private Securities Litigation Reform Act of 1995, which statements can be identified by the use of forward-looking terminology, such as "may", "will", "expect", "intend", "anticipate", "estimate", "predict", "plan" or "continue" or the negative thereof or other variations thereon or comparable terminology referring to future events or results. Forward-looking statements, by their nature, are subject to risks and uncertainties. Tribute actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including general economic conditions, the ability of Tribute to successfully integrate operations, and the timing of expenditures and expansion opportunities, any of which could cause actual results to vary materially from current results or anticipated future results. See Tribute reports filed with the Canadian Securities Regulatory Authorities and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward-looking statements.

Tribute assumes no obligation to update the information contained in this press release to update forward- looking statements to reflect changed assumptions, the occurrence of anticipated events or changes in future operating results, financial condition or business over time.

  • Soriatane and Bezalip are registered trademarks and under license from Actavis Group PTC ehf
  • Cambia is a registered trademark and under license from Nautilus Neurosciences, Inc.
  • Collatamp G is a registered trademark and under license from EUSA Pharma (Europe) Limited
  • Gelfoam is a registered trademark of Pharmacia & Upjohn Company LLC, used under license by Pfizer Canada Inc.

For further information on the Company, visit

(formerly Stellar Pharmaceuticals Inc.)
(Expressed in Canadian dollars)
As at As at
December 31, December 31,
2012 2011
Cash and cash equivalents $ 2,283,868 $ 2,227,973
Accounts receivable, net of allowance of $nil (2011 - $nil) 1,205,087 763,810
Inventories 1,000,557 870,630
Taxes recoverable 261,400 180,160
Loan receivable 15,814 15,814
Prepaid expenses and other receivables 118,910 124,101
Total current assets 4,885,636 4,182,488
Property, plant and equipment, net 1,159,375 1,207,462
Intangible assets, net 10,883,179 10,409,744
Goodwill 3,599,077 3,408,741
Debt issuance costs, net 301,265 -
Total assets $ 20,828,532 $ 19,208,435
Accounts payable and accrued liabilities $ 5,455,664 $ 2,684,542
Amount payable and contingent consideration due - 1,624,289
Current portion of long term debt 1,305,840 -
Total current liabilities 6,761,504 4,308,831
Warrant liability 202,213 2,543
Long term debt 1,815,791 -
Deferred tax liability 314,900 1,524,200
Total liabilities 9,094,408 5,835,574
Contingencies and commitments
Capital Stock
Non-voting, convertible redeemable and retractable preferred shares with no par value
Common shares with no par value
Common shares 39,610,042 (2011 - 37,610,042) 17,589,957 16,469,621
Additional paid-in capital options 1,867,723 1,277,830
Deficit (7,723,556 ) (4,374,590 )
Total shareholders' equity 11,734,124 13,372,861
Total liabilities and shareholders' equity $ 20,828,532 $ 19,208,435
(formerly Stellar Pharmaceuticals Inc.)
(Expressed in Canadian dollars)
For the Years Ended December 31,
2012 2011
Licensed domestic product net sales $ 8,322,945 $ 572,272
Other domestic product sales 2,494,359 1,977,167
International product sales 1,525,479 1,306,215
Royalty and licensing revenues - 14,227
Total revenues 12,342,783 3,869,881
Cost of sales
Licensor sales and distribution fees 5,916,845 484,480
Cost of products sold 1,220,716 932,755
Write down of inventories 36,345 26,117
Gross Profit 5,168,877 2,426,529
Selling, general and administrative 8,870,609 3,034,740
Amortization 718,981 77,951
Total expenses 9,589,590 3,112,691
(Loss) from operations (4,420,713 ) (686,162 )
Non-operating income (expenses)
Change in warrant liability 247,486 214,280
Cost of extending the warrant expiration (135,157 ) -
Change in fair value of contingent consideration 79,724 (57,996 )
Research and development (21,402 ) (49,977 )
Loss on disposal of equipment - (259,636 )
Acquisition and restructuring costs - (671,112 )
Accretion expense (140,154 ) (6,888 )
Interest expense (253,143 ) -
Interest income 13,940 18,910
Loss and comprehensive loss before tax (4,629,419 ) (1,498,581 )
Current income tax recovery 71,153 -
Deferred income tax recovery 1,209,300 976,800
Net loss and comprehensive loss for the year $ (3,348,966 ) $ (521,781 )
Loss Per Share
- Basic $ (0.09 ) $ (0.02 )
- Diluted $ (0.09 ) $ (0.02 )
Weighted Average Number of Common Shares Outstanding
- Basic 39,167,419 25,706,000
- Diluted 39,167,419 25,706,000
(formerly Stellar Pharmaceuticals Inc.)
(Expressed in Canadian dollars)
For the Years Ended December 31,
2012 2011
Cash flows from (used in) operating activities
Net (loss) $ (3,348,966 ) $ (521,781 )
Items not affecting cash:
Deferred income tax recovery (1,209,300 ) (976,800 )
Amortization 772,012 143,505
Loss on disposal of equipment - 259,636
Change in warrant liability (247,486 ) (214,280 )
Cost of extending the warrant expiration 135,157 -
Change in fair value of contingent consideration (79,724 ) 57,996
Stock-based compensation 589,893 332,532
Accretion expense 140,154 6,888
Issuance of equity instruments for services rendered - 14,467
Change in non-cash operating assets and liabilities 1,690,533 (113,611 )
Cash flows (used in) operating activities (1,557,727 ) (1,011,448 )
Cash flows (used in) investing activities
Additions to property, plant and equipment (49,272 ) (9,990 )
Payment of contingent liabilities (40,000 ) -
Increase in patents and licensing agreements (792,902 ) (42,521 )
Cash cost of acquisitions (425,000 ) (1,036,110 )
Cash flows (used in) investing activities (1,307,174 ) (1,088,621 )
Cash flows from (used in) financing activities
Financing costs deferred (341,489 ) -
Long term debt repayment (217,569 ) -
Long term debt issued 3,500,000 -
Share issuance costs - (24,243 )
Cash flows from (used in) financing activities 2,940,942 (24,243 )
Changes in cash and cash equivalents 76,041 (2,124,312 )
Change in cash due to changes in foreign exchanges (20,146 ) -
Cash and cash equivalents, beginning of year 2,227,973 4,352,285
Cash and cash equivalents, end of year $ 2,283,868 $ 2,227,973

Contact Information